Beximco Pharma trading to be suspended on LSE

UNB:

Trading of Global Depositary Receipts (GDRs) for Beximco Pharmaceuticals Limited, one of Bangladesh’s largest drug manufacturers, is set to be suspended on the London Stock Exchange (LSE) starting from January 2, 2026.

The suspension comes after the company failed to publish its audited financial reports for the fiscal year ending June 30, 2024-25 within the mandatory time frame.

According to a disclosure on the LSE website, Beximco Pharma was unable to release its final annual results by the December 31, 2025 deadline required under the London Stock Exchange’s Alternative Investment Market (AIM). Consequently, the exchange is moving to temporarily halt the trading of the company’s GDRs. The company cited ongoing legal complexities as the primary reason for the delay. The dispute involves a decision by the Bangladesh Securities and Exchange Commission (BSEC) to appoint nine additional independent directors to Beximco Pharma’s board following the fall of regime in August 2024.